American clinical stage biotechnology company at Watertown in Massachusetts, founded in 2020 to work on microglia and the TREM2 receptor in neurodegenerative disease, listed in New York and bought by Sanofi in 2025. Developed iluzanebart, an antibody against TREM2 for adult onset leukoencephalopathy with axonal spheroids, and a small molecule TREM2 agonist for Alzheimer's disease, with its own discovery research, biomarker and clinical development programmes.
No hay comentarios disponibles.
Deja tu valoración & comentario